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Background/aim: Sleep deprivation disrupts prepulse inhibition of acoustic startle reflex and can be used to mimic psychosis in experimental animals. On the other hand, it is also a model for other disorders of sensory processing, including migraine. This study
aims to assess the effects of sodium valproate, a drug that is used in a variety of neuropsychiatric disorders, on normal and disrupted
sensorimotor gating in rats.
Materials and methods: Sixty-two Wistar albino rats were randomly distributed into 8 groups. Subchronic and intraperitoneal sodium
valproate were administrated to the sleep-deprived and nonsleep-deprived rats by either 50–100 or 200 mg/kg/day. Prepulse inhibition
test and locomotor activity test were performed. Sleep deprivation induced by the modified multiple platform method.
Results: Sleep deprivation impaired prepulse inhibition, decreased startle amplitude, and increased locomotor activity. Sodium valproate did not significantly alter prepulse inhibition and locomotor activity in nonsleep-deprived and sleep-deprived groups. On the other
hand, all doses decreased locomotor activity in drug-treated groups, and low dose improved sensorimotor gating and startle amplitude
after sleep deprivation.
Conclusion: Low-dose sodium valproate improves sleep deprivation-disrupted sensorimotor gating, and this finding may rationalize
the use of sodium valproate in psychotic states and other sensory processing disorders. Dose-dependent effects of sodium valproate on
sensorimotor gating should be investigated in detail.
Key words: Sleep deprivation, sodium valproate, prepulse inhibition, sensorimotor gating, psychosis, rat

1. Introduction
To model psychotic disorders in experimental animals,
neurodevelopmental, pharmacological, lesion, and genetic
manipulation methods are frequently utilized. However,
there is still no animal model where psychosis can be reflected by its all aspects. Sleep deprivation (SD) may be a
valid psychosis model due to its effects on behavioral, neurochemical, and neurophysiological parameters.
It was reported that, with SD, cognitive, perceptual,
and behavioral symptoms of psychosis in people and behavioral symptoms of psychosis in animals were observed
[1,2]. Psychosis-like behaviors such as hyperactivity, irritability, aggression, perseverative behaviors, and increased
response to psychostimulants are observed in rodents due

to long-term SD [2,3]. Schizophrenia and SD seem to be
causing similar functional connectivity anomalies [4–6]
and neurophysiological [7–11] and neurochemical anomalies [12–16] in the brain. Moreover, the thalamic reticular
nucleus (TRN), which is assumed to have a role in schizophrenia, is the place where the sleep spindles observed in
electroencephalography are produced during NREM sleep,
and evidence shows a decrease in the numbers and intensities of sleep spindles in nonmedicated schizophrenia patients, their first-degree relatives, and SD-applied healthy
individuals [17–19]; these indicate possible common neurophysiological processes between SD and schizophrenia.
For all these reasons, SD may be an ideal model to trigger a
schizophrenia-like psychosis picture in experimental ani-
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mals not only because it induces psychosis-like symptoms
on the behavioral dimension but also because it probably
partially imitates psychosis-related neurophysiological
and neurochemical mechanisms.
Furthermore, with SD, the prepulse inhibition (PPI)
test is disrupted in humans and animals [20,21]. As
known, PPI refers to inhibition of the startle response by
a weaker stimulus that does not lead to startling and that
comes before a strong sensory stimulus that leads to startling [22]. The phenomenon of PPI seen in all mammals is
a relatively constant neurobiological marker [23], and it is
used as a measurement of sensorimotor gating [24]. It is
accepted that agents reversing the PPI that is disrupted in
schizophrenia have therapeutic potential. Usage of SD as
a psychosis model was proposed as it disrupts PPI in both
humans and animals [25].
On the other hand, dysregulation of sensory processing is suggested in several neurological disorders such as
migraine. Migraine is characterized by the central sensitization of the trigemino-thalamic pathway that results in
a sensitivity to certain modalities of sensorial input [26],
and somatosensory gating is thought to be altered [27,28].
Hence, SD is used as an experimental model for migraine
[29] or for other sensory processing disorders such as mania [30].
This study aimed to investigate the effect of sodium valproate (SVA), a widely used antiepileptic/mood stabilizer
(MS) drug in several neuropsychiatric disorders, on sensorimotor gating in sleep-deprived and nonsleep-deprived

rats. The effects of SVA on post-SD sensorimotor gating
have not been assessed before. Here, 72-h SD was used to
mimic psychosis via disruption of prepulse inhibition, and
effects of SVA, an add-on treatment in psychotic disorders,
on this model were investigated by using the PPI test and
locomotor activity test.
2. Materials and methods
2.1. Animals and laboratory
All
experiments
were
performed
at
the
Neuropsychopharmacology Application and Research
Center (NPARC) of Üsküdar University. Sixty-two
14–16-week-old Wistar albino male rats were randomized
into a total of eight groups including 4 groups without SD
(nonsleep-deprivation; NSD) and 4 groups with SD. Two
groups had 7 rats while others had 8 rats in each. Both
the NSD and SD groups consisted of vehicle groups and
SVA-administrated groups with doses of 50 mg/kg/day,
100 mg/kg/day, and 200 mg/kg/day. Injections were made
intraperitoneally for 4 days 2 times a day as in the morning
and the evening, and after the last injection in the morning
of the 5th day, the experiments were started.
Throughout the experiment, the animals were kept
at a suitable room temperature (22 ± 2 °C), 40%–45%
humidity, 12 h of light/dark cycles (light in the period of
07:00–19:00), and in a way that they would have access to
food and water ad libitum. The subjects on which SD was
applied were housed in a water tank for 72 h. The summary
of the experimental protocol may be seen in Table 1.

Table 1. Experiment protocol.
Groups

Number of
rats (n)

Vehicle

8

SVA 50 mg/kg/day

7

NSD SVA 100 mg/kg/day

8

SVA 200 mg/kg/day

7

Vehicle

8

SVA 50 mg/kg/day

8

SVA 100 mg/kg/day

8

SVA 200 mg/kg/day

8

SD

Hours

Day 1

Day 2

Day 3

Day 4

Day 5

09:00
17:00
09:00
17:00
09:00
17:00
09:00
17:00
09:00
17:00
09:00
17:00
09:00
17:00
09:00
17:00

S/HC
S/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
S/HC
S/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC

S/HC
S/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
S/WT
S/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT

S/HC
S/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
S/WT
S/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT

S/HC
S/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
SVA/HC
S/WT
S/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT
SVA/WT

S/HC
SVA/HC
SVA/HC
SVA/HC
S/WT
SVA/WT
SVA/WT
SVA/WT
-

NSD: nonsleep deprivation, SD: sleep deprivation, S: saline, SVA: sodium valproate, HC: home cage, WT: water tank.
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2.2. Ethical issues
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health,
USA, which was published and released in 1996. The
protocol was approved by the Local Ethics Committee of
Üsküdar University on June 23, 2016 with the approval
number of 2016-13.
2.3. Drug
This study used the 400 mg/4 mL intravenous form of SVA
(Depakin®, Sanofi-Aventis, France) that is parenterally
applied in humans, and each vial contained 400 mg of
SVA. As the drug could be used intraperitoneally in
experimental animals [31], it was applied in each injection
by dissolving in 0.5 mL of saline. In the vehicle groups,
each injection contained only 0.5 mL of saline.
2.4. Prepulse inhibition test
For measurement of the PPI of the acoustic startle
reflex, an SR-LAB Startle Response System (San Diego
Instruments, San Diego, California, USA) was used.
The device for the PPI test consisted of four isolation
cabinets, software, control unit, and animal enclosures.
All animals were handled for 3 days prior to the start of
the experiments to prevent anxiety, fear and/or stress of
rats that could impair the startle response [32]. The rats
were placed into the Plexiglas cylinders of the cabinets
for 15 min for adaptation 24 h before the test. On the
test day, the test protocol was applied. PPI% was defined
as a decrease in the amplitude of the startle reflex in the
presence of a prepulse stimulus and calculated for each
of the three different prepulse intensities by using the
𝜌𝜌!
***
following formula: 𝑃𝑃𝑃𝑃𝑃𝑃% = &1 −
, × 100, where ρ+ is
***
𝜌𝜌_
the startle amplitude with the prepulse, and ρ- is the startle
amplitude without the prepulse. After each session, the
chambers were cleaned with ethanol. In order to prevent
the habituation of the animal, intersession intervals were
at least 1 week [33].
2.4.1. Test protocol
The animals that were handled by the researcher for the first
3 days (D1-3) before the test were kept in the measurement
boxes without stimulation for 15 min for their getting used
to the device on D4, and the PPI test was ran on D5. This
test starts with the habituation step lasting for 5 min where
no stimulation is given, and only the background sound is
present. In the following step, five 120 dB auditory stimuli
are given. The blocks of stimuli are then consecutively
repeated eight times. In each of these blocks, five different
auditory stimuli with randomly changing orders are
applied with random intervals (varying between 10 and 30
s). These are:
1. 40-ms 120 dB auditory stimulus,
2. 40-ms 120 dB auditory stimulus 100 ms after a
20-ms basal + 4 dB prestimulus,
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3. 40-ms 120 dB auditory stimulus 100 ms after a
20-ms basal + 8 dB prestimulus,
4. 40-ms 120 dB auditory stimulus 100 ms after a
20-ms basal + 16 dB prestimulus,
5. Background sound only (this stimulus is for
controlling responses arising from the rat’s movement
within the cage).
Finally, 5 startle stimuli given at the beginning of the
measurement are applied again at random intervals (10–30
s), and the startle response is assessed. The entire protocol
lasts approximately 26 min.
2.5. Locomotor activity test
The locomotor activity (LMA) test was carried out in an
open-field activity monitoring system with nine soundinsulated chambers with dimensions of 40 × 40 × 30 cm
(MAY 9908, Commat Ltd., Ankara, Turkey). The activity of
the subjects was monitored and analyzed by an automated
video-tracking device and software (Noldus, Ethovision
v3.1, Netherlands). LMA was measured by determining
the amount of “total distance moved” for the 30-minutelong test period.
2.6. Modified multiple platform technique
SD induction by this technique is dependent on that, when
rats that are forced to stand on small platforms placed into
a water-filled tank enter REM sleep, their muscles lose
tone, their tails contact the water, and thus, they awaken
from the REM sleep. While it is usually reported that
this mainly induces SD unique to the REM stage of sleep,
studies have stated that it also affects the NREM stage at
rates reaching about 40% [34]. Upon understanding that
this technique induces anxiety in animals, it was proposed
that this anxiety could be reduced by testing animals living
in the same cage together [35] and allowing them to move
freely among multiple platforms placed into the tank [36].
This way, the technique was modified in a way to allow the
animals to be tested together and by moving. In different
studies in the literature, tanks were used in different
dimensions [37,38]. In this study, to trigger SD, a Plexiglas
water tank with dimensions of 125 × 43 × 45 cm was used.
Inside the tank, 14 platforms with a diameter of 6.5 cm and
height of 16 cm each were placed so that they would have
a distance of 10 cm from each other. The water tank was
filled with water up to the last 1 cm of the platforms, that is,
at a height of 15 cm. The water temperature was adjusted
at 23 ± 1 °C. The tank was covered with grills that allowed
access to water and food like in the cages. The animals of
an entire group were put into the tank simultaneously.
2.7. Statistical analysis
The statistical analysis of the data was performed using
the PSPP Statistical Analysis Software 1.2.0 (GNU, Boston, MA, USA) and RStudio 1.3.1093 (RStudio, PBC, Boston, MA, USA). As the hypothesis of normal distribution
(the Shapiro–Wilk test) was rejected, nonparametric tests
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were used for the statistical analysis. The effects of drug
treatment and SD on PPI% were analyzed using the F1F1
function of R Program nparLD package, a nonparametric
test for mixed analysis of variance with repeated measures,
where drug treatment or SD was the whole-plot factor
and prepulse intensity was the repeated one. We reported
ANOVA-type statistics (ATS). The Kruskal–Wallis test was
used to compare the basal mean PPI% among all groups,
startle amplitude, and total distance moved values of SVAtreated NSD or SD groups. The Mann–Whitney U test
was used to compare startle amplitude and total distance
moved values of the vehicle groups. A value of p < 0.05 was
considered statistically significant.
3. Results
A nonsignificant difference between the basal mean PPI%
of all groups indicates that the groups are similar in terms
of the basal mean PPI% [X2 (7) = .66, p = .99 > .05]. All
data including the basal mean PPI%, mean PPI%, startle
amplitude, and total distance moved are shown in Table 2.
The weights of the subjects are shown in Table 3.
3.1. SVA effects in NSD groups
Figure 1 shows the effects of SVA on PPI% with 74 dB, 78
dB, and 86 dB prepulses, respectively. The nparLD F1F1 test
revealed a significant main effect of prepulse intensity on
PPI% [ATS (1.72) = 101.00, p = .00 < .05], a nonsignificant
main effect of SVA on PPI% [ATS (2.83) = 1.30, p = .27 >
.05] and a nonsignificant effect of interaction [ATS (4.71)
= .44, p = .80 > .05]. There was no significant effect of SVA
in the NSD groups on the startle values [X2 (3) = 6.32, p
= .09 > .05] (Figure 2) or the total distance moved (LMA)
values [X2 (3) = 3.46, p = .32 > .05] (Figure 3).
3.2. SD effects
Figure 4 shows the effects of SD on PPI% with 74 dB, 78
dB, and 86 dB prepulses, respectively. The nparLD F1F1

test revealed a significant main effect of prepulse intensity
on PPI% [ATS (1.91) = 34.23, p = .00 < .05], a significant
effect of SD on PPI% [ATS (1.00) = 5.61, p = .01 < .05] and
a nonsignificant effect of interaction [ATS (1.91) = 2.48,
p = .08 > .05]. There was a significant difference between
the startle values of the SD vehicle (mdn = 44.90) and
vehicle (mdn = 84.25) groups [U = 11, z = –2.21, p = .02 <
.05] (Figure 5). There was a significant difference between
the total distance moved values of the SD vehicle (mdn =
977.86) and vehicle (mdn = 683.31) groups [U = 7, z =
–2.63, p = .00 < .05] (Figure 6).
3.3. SVA effects in SD groups
Figure 7 shows the effects of SVA in the SD groups on
Table 3. Weights of subjects.
Groups
Vehicle
SVA 50 mg/kg/
day
NSD SVA 100 mg/kg/
day
SVA 200 mg/kg/
day
Vehicle
SVA 50 mg/kg/
day
SD SVA 100 mg/kg/
day
SVA 200 mg/kg/
day

Number of rats
(n)
8

Weight ± s.d.
323.50 ± 25.24

7

309.42 ± 48.65

8

307.25 ± 43.03

7

360.00 ± 42.11

8

299.50 ± 39.47

8

351.87 ± 40.96

8

295.12 ± 19.19

8

319.50 ± 37.02

NSD: nonsleep deprivation, SD: sleep deprivation, SVA: sodium
valproate, s.d.= standard deviation.

Table 2. Basal mean PPI%, mean PPI%, startle amplitude, and total distance moved values of all groups.

Vehicle

Mean PPI% ± s.d.
Number Basal mean
Startle amplitude
of rats PPI% ± s.d.
78 dB
86 dB
± s.d.
(n)
74 dB prepulse prepulse
prepulse
8
50.37 ± 14.74 51.86 ± 16.40 69.14 ± 11.70 78.55 ± 10.55 78.65 ± 17.53

SVA 50 mg/kg/day

7

Groups

NSD SVA 100 mg/kg/day 8
SVA 200 mg/kg/day 7

SD

Vehicle

8

SVA 50 mg/kg/day

8

SVA 100 mg/kg/day 8
SVA 200 mg/kg/day 8

52.14 ± 15.72 59.86 ± 11.45 74.14 ± 6.73 82.32 ± 6.24 71.61 ± 20.33
49.25 ± 15.12 56.27 ± 25.66 78.37 ± 9.93 85.46 ± 8.12 122.53 ± 94.33

52.14 ± 10.31 57.67 ± 12.88 71.50 ± 10.76 75.30 ± 12.61 67.45 ± 57.39
50.00 ± 13.86 34.07 ± 22.79 41.58 ± 22.50 62.84 ± 27.46 63.88 ± 61.44
52.87 ± 13.41 36.60 ± 26.88 50.38 ± 25.94 69.90 ± 10.00 146.40 ± 105.42
54.25 ± 13.18 17.99 ± 44.99 21.64 ± 31.95 56.59 ± 17.69 43.88 ± 33.63
52.75 ± 16.10 16.68 ± 47.08 30.18 ± 28.77 45.89 ± 37.21 56.26 ± 92.89

Total distance
moved (cm) ±
s.d.
656.26 ± 303.33
438.76 ± 140.24
435.41 ± 178.73
446.73 ± 156.23
982.17 ± 173.69
688.97 ± 184.10
796.07 ± 219.35
806.39 ± 233.95

NSD: nonsleep deprivation, SD: sleep deprivation, SVA: sodium valproate, s.d.= standard deviation.
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150

50

100

0

unit

100

74 dB

78 dB

86 dB

0

prepulses
Vehicle
SVA 100 mg/kg/d

startle amplitude

SVA 50 mg/kg/d
SVA 200 mg/kg/d

Figure 1. Prepulse inhibition percentage across nonsleep
deprivation groups for different prepulse intensities. PPI% values
are different in different prepulse intensities (p < .05) (not denoted).
SVA does not have a significant effect on PPI% (p > .05). Error bars
represent standard deviations. NSD: nonsleep deprivation, SVA:
sodium valproate, PPI: prepulse inhibition, dB: decibel.

Vehicle

1500

200

1000
500
0

100

total distance moved

0

Vehicle

Vehicle

SVA 50 mg/kg/d

SVA 100 mg/kg/d

SVA 200 mg/kg/d

Figure 2. Startle amplitude across nonsleep deprivation groups.
SVA does not have a significant effect on startle amplitude (p >
.05). Error bars represent standard deviations. NSD: nonsleep
deprivation, SVA: sodium valproate.

cm

1500
1000

0
total distance moved
Vehicle

SVA 50 mg/kg/d

SVA 100 mg/kg/d

SVA 200 mg/kg/d

Figure 3. Total distance moved across nonsleep deprivation
groups. SVA does not have a significant effect on total distance
moved (p > .05). Error bars represent standard deviations. NSD:
nonsleep deprivation, SVA: sodium valproate.
PPI%

*

*

74 dB

78 dB

86 dB

prepulses
Vehicle

SD-vehicle

Figure 4. Prepulse inhibition percentage across vehicle groups
for different prepulse intensities. PPI% values of NSD groups
are different (p < .05) (not denoted). There are significant
PPI% differences between vehicle and SD-vehicle groups with
different prepulse intensities (denoted with *, p < .05). Error
bars represent standard deviations. SD: sleep deprivation, PPI:
prepulse inhibition, dB: decibel.
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50
0

74 dB

78 dB

86 dB

prepulses
Vehicle

SVA 50 mg/kg/d

SVA 100 mg/kg/d

SVA 200 mg/kg/d

Figure 7. Prepulse inhibition percentage across sleep deprivation
groups for different prepulse intensities. PPI% values are different
in different prepulse intensities (p < .05) (not denoted). SVA does
not have a significant effect on PPI% with different prepulses (p
> .05). Error bars represent standard deviations. SVA: sodium
valproate, PPI: prepulse inhibition, dB: decibel.

*

100

0

100

-50

500

SD-vehicle

Figure 6. Total distance moved across vehicle groups. SD has
a significant effect on total distance moved (denoted with *,
p< .05). Error bars represent standard deviations. SD: sleep
deprivation.

PPI%

startle amplitude

50

SD-vehicle

Figure 5. Startle amplitude across vehicle groups. SD has a
significant effect on startle amplitude (denoted with *, p < .05).
Error bars represent standard deviations. SD: sleep deprivation.

cm

300

unit

50

*

PPI%
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PPI% with 74 dB, 78 dB, and 86 dB prepulses, respectively.
The nparLD F1F1 test revealed a significant main effect
of prepulse intensity on PPI% [ATS (1.96) = 35.64, p =
.00 < .05], a nonsignificant effect of SVA on PPI% [ATS
(2.91) = 1.16, p = .32 > .05] and a nonsignificant effect of
interaction [ATS (5.01) = .59, p = .70 > .05]. There was a
significant effect of SVA in the SD groups on the startle
values [X2 (3) = 9.20, p = .02 < .05] (Figure 8). The Mann–
Whitney U test revealed a significant difference between
vehicle (mdn = 44.90) and SVA 50 mg/kg/day group (mdn
= 119.90) [U = 13.00, z = –2.00, p = .04 < .05]. There was
also a nonsignificant effect of SVA on the total distance
moved values [X2 (3) = 7.59, p = .055 > .05] (Figure 9).
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unit

400
200
0
-200

startle amplitude
Vehicle

SVA 50 mg/kg/d

SVA 100 mg/kg/d

SVA 200 mg/kg/d

Figure 8. Startle amplitude across sleep deprivation groups. SVA
50 mg/kg/day has a significant effect on startle amplitude compared to vehicle (denoted with *, p < .05). Error bars represent
standard deviations. SVA: sodium valproate.

cm

1500
1000

500
0

total distance moved
Vehicle
SVA 100 mg/kg/d

SVA 50 mg/kg/d
SVA 200 mg/kg/d

Figure 9. Total distance moved across sleep deprivation groups.
SVA does not have a significant effect on total distance moved
(p > .05). Error bars represent standard deviations. SVA: sodium
valproate.

4. Discussion
This study firstly showed that SVA did not have a statistically significant effect on the PPI%, startle, and LMA in the
rats at the subchronic intraperitoneal doses of 50–100 and
200 mg/kg/day. Secondly, it was shown that 72-h SD significantly disrupted the PPI, decreased the startle, but increased the LMA in the rats. Afterward, it was determined
that the SVA application at the same doses did not have
a statistically significant effect on the disrupted PPI and
increased LMA by SD. On the other hand, SVA 50 mg/kg/
day administration after SD significantly increased startle
amplitude.
The main treatment of the condition of schizophrenia
is achieved by antipsychotic drugs, while polypharmacy
practices where MSs are added to existing antipsychotic
treatments are very common. As there are few data supporting SVA usage in schizophrenia treatment, the drug
usage is off-label, but its usage for this indication is prevalent [39]. According to studies, the frequency of adding
SVA to schizophrenia treatment varies in the range of
15%–50% [40]. The reason for using SVA in schizophrenia patients is frequently associated with achieving impulse control and reducing aggression in patients that do
not respond to classical treatment [40]. There are studies
suggesting that SVA reduces aggression in schizophrenia
patients. For example, it was shown that SVA reduces aggression in schizophrenia patients receiving risperidone or

olanzapine treatment [41]. The effectiveness of SVA, which
is a GABAergic drug, in schizophrenia, which is a disorder
that is considered to be characterized by mesolimbic dopamine increase, is associated with its reduction of dopaminergic activity [42].
As known, PPI is disrupted in several psychiatric disorders, especially schizophrenia. It is accepted that drugs
that are shown to reverse this disruption have an antipsychotic potential. In addition, little is known about the action mechanisms of MSs on PPI. A study conducted in
2006 by Umeda et al. [43] investigated the effects of MSs
on PPI disrupted by apomorphine and MK-801 in mice.
Accordingly, it was seen that valproate (30–300 mg/kg,
i.p.) did not have any effect on PPI by itself, but it reversed
the PPI disruption caused by apomorphine (1 mg/kg, s.c.),
and as it did not induce any effect on the PPI disrupted
by dizocilpine (0.3 mg/kg, s.c.), it was thought that it induces its effect through the dopaminergic system. Again,
in rodent models, it was reported that valproate (100 mg/
kg) did not affect PPI disruption induced by ketamine or
amphetamine [44]. In an epigenetic schizophrenia mouse
model induced by methionine, it was determined that valproate (1.5 mmol/kg) did not have an effect by itself on
PPI, but when used together, it antagonized the reduction
in PPI created by methionine [45].
Similar to the aforementioned studies, in this study, it
was also shown that SVA did not have a significant effect
on the PPI at the tested doses. However, although the difference was not statistically significant, SVA reduced the
LMA at all doses that were used. It is expected that the
LMA of rodents would decrease in the open field test in relation to anxiety [46]. Furthermore, many studies reported
the anxiolytic properties of SVA [47,48]. For this reason,
observation of a decrease in the LMA in this study by SVA
was not an expected effect. However, it was considered that
the known sedation effect of SVA [49] could have reduced
the LMA.
SD, which was applied at the second stage of the study,
behaviorally induces a psychosis-like picture without any
pharmacological intervention. It was reported that, in humans, anxiety, irritability, and perceptual distortions start
by 24–48 h of SD, expected disorders and hallucinations
are seen in 48–90 h, and delusions emerge after 72 h [50].
As this psychosis-like picture emerges after 48 h, in this
study, the rats were subjected to SD for 72 h. The disruption of the sensorimotor gating and presence of hyperactivity in the rats after SD indicate that the model may be
used as a psychosis model in experimental animals.
It was observed that SVA, which started to be applied
24 h before 72-h SD and continued for a total of 4.5 days,
did not create a statistically significant effect on the PPI%
at doses of 50–100 and 200 mg/kg/d. However, although
the difference was not significant, the 50 mg/kg/day form
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of SVA increased the already reduced PPI% at all prepulses, while the other doses appeared to reduce it even more.
Likewise, at the applied doses, while SVA did not have a
statistically significant effect on LMA, it appeared to reduce the LMA increased by SD (p = .057). At this point,
SVA 50 mg/kg/day was the only dose reducing the LMA
most, and it also significantly normalized the decreased
startle amplitude levels by SD.
Considering animal models, the positive effects of
SVA on sensorimotor gating are reported. In a schizophrenia mouse model, it was reported that SVA applied
prophylactically for 14 days at 200 mg/kg 2×1 prevented
PPI deficits and hyperactivity [51]. Another study showed
that SVA acutely applied at 178–316 mg/kg increased
the PPI% of mice with naturally low PPI [52]. Similarly,
there are also studies and case reports suggesting that
SVA reduces psychotic symptoms in schizophrenia when
it is added to an ongoing antipsychotic treatment. It was
reported that the addition of 1700 mg/day of SVA to the
treatment of a patient with functional hallucinations receiving antipsychotic treatment improved hallucinations
and noticeably increased the functionality of the patient
[53]. A double-blind, randomized study determined that
the addition of SVA by about 2300 mg to the treatment of
olanzapine or risperidone at acute exacerbation of schizophrenia achieved a reduction in psychotic symptoms by
using PANSS and BPRS [54]. In an open-label study where
SVA was added at a mean dose of 1600 mg/day to the treatments of 28 schizophrenia patients with long disease durations, it was reported that 9 of the patients responded well
to the treatment, 12 responded partially, and 7 did not respond or responded negatively (n = 2) [55]. Furthermore,
in a review containing randomized controlled studies, it
was reported that there is only limited evidence that SVA
added to antipsychotic treatment improves the general
clinical response, especially aggression [56]. Likewise, in a
detailed review containing several studies, it was reported
that adding SVA to the treatment in schizophrenia has a
very limited benefit [57]. On the other hand, to the best of
our knowledge, there are no broad-scaled studies reporting
on the worsening effect of SVA on psychotic symptoms in
psychotic patients. As in a study by Suzuki et al. [55], while
it was noted that worsening was observed in schizophrenia
patients who were given additional SVA treatment, diffuse
negative effects were not mentioned. Probably for these
reasons, the tendency of clinicians towards adding SVA to
schizophrenia treatment is stronger.
On the other hand, low-dose SVA (500–1000 mg/day)
is used in prophylaxis of migraine [58]. Action mechanisms of SVA include inhibition of voltage-dependent
sodium channels and T-type calcium currents, potentiation of GABA concentrations via GABA-synthesizing and
degrading enzymes, and modulation of the extracellular
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signal-regulated kinase pathway [59]. Consequently, it
decreases neurogenic inflammation and prevents central
sensitization that are results of cortical spreading depression, a phenomenon that has a prominent role in migraine
pathophysiology [60].
In addition, it was showed that SVA prevents CSD-mediated activation of TRN [31], a GABAergic region within
the thalamocortical circuit that has a role in sensory gating
that is suggested to dysfunction in schizophrenia and migraine [5,31]. Hence, in considering the positive effects of
low-dose SVA in both migraine treatment and sensorimotor gating, future studies may focus on revealing how SVA
acts on particular brain regions related to sensorimotor
gating. Moreover, low and high SVA were shown to have
different pharmacological effects on the brain. It was reported that SVA affects GABA and aspartate metabolism
at low doses, and as the dose rises, it begins to increase
serotonin and other monoamine levels, decrease succinic
semialdehyde dehydrogenase, decrease ATP levels, inhibit
sodium currents, increase glutamate release, modulate
calcium and potassium conductance, and inhibit GABA
transaminase [61]. Therefore, it may be suggested that
positive effects of low-dose SVA on sensorimotor gating
following SD arise from its effects on GABA, aspartate
and/or monoamines; nevertheless, dose-dependent effects
of SVA, especially in brain regions involved in sensorimotor gating, should be investigated.
While it is not possible to completely adapt the data
obtained in this study to humans, the drug doses used in
this study were based on the doses used in humans. In
studies with experimental animals, to determine the corresponding dose of drugs in humans, the formula “Human
equivalent dose (mg/kg) = Animal dose (mg/kg) × [Animal Km / Human Km]” is used [62]. Km is the correction
factor, whereas it is found by dividing the average weight
of the species (kg) by the body’s surface area (m2). Accordingly, the SVA doses used in this study corresponded
to 567 mg/day, 1135 mg/day, and 2270 mg/day for a 60
kg person. While the doses of SVA used in humans are
adjusted based on plasma levels, they frequently vary in
500–2500 mg. Therefore, in this study, SVA was used in a
broad dose range to reflect the clinical usage of the drug
substantially.
This study had some limitations. The plasma levels of
SVA were not checked in the study, and as it is a parenteral
medication application, it was assumed that it showed the
known pharmacodynamic and pharmacokinetic effects.
Moreover, in a similar study conducted on rats before [63],
the authors determined that the plasma drug (gabapentin)
levels were halved after SD. As the pharmacokinetic properties of drugs may vary with the effect of SD, it is possible
that SVA levels could also be changed, but this possibility
was not examined. Additionally, the application of SVA for
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a longer time than that in this study may lead to the observation of different effects. Another limitation was that
the study did not use a sham group where the effects of
the water tank could be assessed. Nevertheless, in previous SD studies conducted at our laboratory, the sole effect
of the water tank was examined by using a sham group,
and it was observed that the sensorimotor gating in this
group did not change, but LMA increased by a bit, while it
was not as noticeable as the increase in the SD group. With
the purpose of using a smaller number of subjects, reassessment of the sham effect was not considered necessary.
The fact that two groups in the study included 7 rats rather
than 8 was another limitation, and it may have affected the
results.
This study where the effects of SVA on sensorimotor
gating disrupted by SD were investigated is the first one
in the literature to the best of our knowledge. In studies
examining the effects of SVA, PPI was frequently disrupted
by using pharmacological agents, and the effects of SVA
on this disruption were then investigated. In this study,
on the other hand, the behavioral symptoms of psychosis
were induced via SD and without using a pharmacological

method. Although projecting data obtained from experimental animals directly onto humans would not be convenient, this study suggested that, in psychotic pictures, sole
medium-high dose SVA usage may affect sensorimotor
gating negatively, while low-dose usage may have a positive effect. This situation may indicate that the drug has
dose-dependent effects on sensorimotor gating. Again,
the fact that SVA shows sedative effects in a broad dose
range may explain its clinical activity reported in psychotic
pictures. It seems necessary to investigate the benefits and
risks of using SVA in psychotic pictures in more detail. On
the other hand, in persons with sensorimotor gating disorders that do not show explicit psychotic symptoms, usage
of SVA for other reasons may have a possibility of triggering psychotic symptoms. In this sense, it may be necessary
for clinicians to more strictly monitor especially patients
with a history of psychiatric disorders in their family.
Informed consent
The study protocol was approved by the Local Ethics
Committee of Üsküdar University on June 23, 2016 with
the approval number of 2016-13.
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